https://www.selleckchem.com/pr....oducts/penicillin-st
There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors. Pooled analysis of individual patient-level data from MONARCH 2 and 3 trials. Patients were classified according to baseline BMI into underweight (18.5 kg/m2), normal (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2) and obese (≥30 kg/m2) and divided into two treatment groups abemaciclib + ET vs. placebo + ET. Primary endpoint was
Like
Comment
Share
